arrow
V

Vito Amoroso

University of Brescia
H指数:23
被引数:1,853

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Presentation, Prognosis, and Treatment Strategies for Thymoma-Associated Multiorgan Autoimmunity: A Pooled Analysis.

胸腺瘤相关多器官自身免疫的临床表现、预后及治疗策略:一项合并分析。

2025-12-030
PRE
Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management

神经内分泌肿瘤骨转移:一项关于自然史和管理的意大利全国性调查结果

2025-11-180
OAAI
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)

非功能性晚期GEP-NENs的管理临床实践指南:意大利医学肿瘤学会(AIOM)与意大利神经内分泌肿瘤学会(ITANET)合作,采用GRADE方法进行证据评估和推荐。

2025-11-120
OAAI
Body composition in early breast cancer patients treated with adjuvant aromatase inhibitors: Does dietary counseling matter?

接受芳香化酶抑制剂辅助治疗的早期乳腺癌患者的身体成分: 饮食咨询重要吗?

BREAST
IF7.9
2024-12-010
OAAI
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database
2024-01-043
OAAI
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial

评估卡博替尼联合兰瑞肽在胃肠胰腺和胸部神经内分泌肿瘤中的安全性和活性: II期LOLA试验的原理和方案

2023-09-266
OAAI
Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy
2023-09-115
OAAI
Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report

Sacituzumab govitecan和放射疗法治疗转移性,三阴性和BRCA突变的活动性脑转移的乳腺癌患者: 病例报告

2023-02-208
OAAI
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (carcinoid): Results from the Phase 2 ATLANT Study
2022-08-3113
PRE
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial

依维莫司联合芳香化酶抑制剂作为一线化疗后的维持治疗: III期随机main-a (维持Afinitor) 试验的最终结果

2021-09-0110
OAAI